
Sign up to save your podcasts
Or


Dr. Sarah Goldberg, from Yale Cancer Center, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified during first line chemotherapy. When should we switch treatments?
By cancerGRACE - H. Jack West, MDDr. Sarah Goldberg, from Yale Cancer Center, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified during first line chemotherapy. When should we switch treatments?

2 Listeners

1 Listeners

0 Listeners

0 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners